| Precision Therapeutics is a CLIA-certified clinical laboratory |
Ovarian Cancer Ongoing Trials:
- PT-103: Retrospective Case Control Study to Develop a Training Set for a Cross Validated Chemoresponse Marker Algorithm in Cases with Ovarian, Peritoneal or Fallopian Tube Cancer The purpose of this study is to improve upon and validate the prognostic and/or predictive accuracy of a drug response marker by the development of improved alternative algorithms based on the actual clinical outcome of retrospective cases.
- PT-106: Retrospective Case Study to Determine the Correlation of Patient Outcome to the ChemoFx® Assay in Cases with Late Stage Endometrial Cancer The purpose of this study is to assess the relationship of assay sensitive patients versus assay resistant patients with progression free survival.
- PT-206: ChemoFx® PRO - A Post-Market Data Collection Study Utilizing Physician Reported Outcomes This study aims to utilize physician reported outcome data from the first chemotherapy administered following a ChemoFx® final report to generate hypotheses for further sub-study.
The study will also look for trends and common factors among different people's cancer and their sensitivities to chemotherapy treatments. For more information, send an email to observationalstudy@ptilabs.com.
- PT-301: A Non-Interventional Prospective Study of the Correlation of the Precision Therapeutics, Inc. Chemoresponse Assay with Progression-Free Survival in Patients with Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer This study will determine the ability of two tests, the ChemoFx® Assay and the Yale Apoptosis Assay, to predict the success of chemotherapy in recurrent, persistent or refractory cancer of the ovaries, fallopian tube(s) or peritoneum by measuring progression free survival.
Breast Cancer Ongoing Trials:
-
NSABP B-40: Prospective Breast Cancer Study: A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
This study is sponsored by NSABP; Precision Therapeutics is a collaborating laboratory.
This randomized phase III trial is studying six different chemotherapy regimens to compare how well they work with or without bevacizumab in treating women with palpable and operable breast cancer.
- PT-304: Prediction of Response to Neoadjuvant Chemotherapy in Women with Operable Breast Cancer The objective of this study is to develop a biomarker to predict pathological complete response in women treated with neoadjuvant chemotherapy for breast cancer. Such a biomarker would assist physicians in selecting the most effective chemotherapy for the individual patient.
- SWOG S0800: A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (NAB-Paclitaxel) (NSC-736631) with or without Bevacizumab, Either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide© Plus Pegfilgrastim (PEG-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced HER-2/NEU Negative Breast Cancer This study is sponsored by SWOG; Precision Therapeutics is a collaborating laboratory.
This study will compare how well paclitaxel albumin-stabilized nanoparticle formulation, doxorubicin, cyclophosphamide, and pegfilgrastim work when given with or without bevacizumab in women with inflammatory or locally advanced breast cancer.
Information from this website was gathered from ClinicalTrials.gov.
ClinicalTrials.gov provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.
Content last reviewed 04-30-10